Noah Editorial
Blog
Timely research perspectives, biotech market signals, and clinical updates in a cleaner long-form reading format.
November 4, 2026
•ComparisonBest ScholarAI Alternatives for Biomedical Literature Discovery (2026)
Discover five ScholarAI alternatives for biomedical literature research in 2026, with AI paper search, citation verification, and an RSV clinical trial example.
By Linda
November 4, 2026
•Use CasesColorectal Cancer Indication Strategy (2026): EGFR, KRAS, Clinical Competition & R&D Opportunities
Explore colorectal cancer indication strategy in 2026, covering EGFR, KRAS, BRAF, biomarker-defined treatments, clinical competition, and R&D opportunities.
By Linda
November 4, 2026
•Use CasesOncology Clinical Trial Endpoints Beyond OS: PFS, EFS, pCR & PROs (2026)
Compare oncology clinical trial endpoints beyond OS, including PFS, EFS, pCR, ORR and PROs, with real KEYNOTE-522 evidence and FDA/HTA perspectives.
By Linda
November 4, 2026
•ComparisonBest Avidnote Alternatives for Biomedical Literature Research (2026)
Compare 5 Avidnote alternatives for biomedical literature research in 2026, including Noah AI, Elicit, SciSpace, Consensus, and ResearchRabbit.
By Linda
November 3, 2026
•How-toHow to Do a Literature Review with AI: Step-by-Step Guide (2026)
Learn how to do a literature review with AI in 7 steps, from defining a research question and searching papers to evidence synthesis and citations.
By Linda
November 3, 2026
•ComparisonBest Afforai Alternatives for Reviewing Multiple Medical Papers (2026)
Compare the best Afforai alternatives for reviewing multiple medical papers in 2026, including Noah AI, Elicit, SciSpace, Paperguide, and Consensus.
By Linda
November 3, 2026
•ComparisonNoah AI vs Undermind for Deep Literature Research (2026)
Compare Noah AI vs Undermind for deep literature research in 2026. Explore biomedical evidence synthesis, paper discovery, source citations, and research gaps.
By Linda
November 3, 2026
•Use CasesBIRC5/Survivin Target Evaluation: Mechanisms, Clinical Evidence & R&D Strategy (2026)
Explore BIRC5/survivin biology, YM155 clinical trials, LY2181308, SurVaxM immunotherapy, and R&D opportunities in this evidence-based target evaluation.
By Linda
November 3, 2026
•ComparisonBest Enago Read Alternatives for Clinical Paper Analysis (2026)
Explore five Enago Read alternatives for clinical paper analysis in 2026. Compare Noah AI, SciSpace, Elicit, Scholarcy, and Consensus with a real RCT example.
By Linda
November 3, 2026
•Use CasesMAPK1/ERK2 Target Evaluation: Biology, Clinical Evidence, Resistance & R&D Opportunities (2026)
Explore MAPK1/ERK2 as an oncology drug target through an AI-assisted evaluation of pathway biology, target validation, ERK inhibitor clinical evidence, resistance mechanisms, biomarkers, and R&D opportunities. The analysis includes ulixertinib and other ERK1/2 inhibitor programs, highlighting clinical limitations and potential strategies for differentiated drug development.
By Linda
November 3, 2026
•ComparisonNoah AI vs Anara for Cited Biomedical Literature Reviews (2026)
Compare Noah AI and Anara for cited biomedical literature reviews in 2026, with real Noah evidence screenshots, source verification, and clinical trial examples.
By Linda
November 3, 2026
•ComparisonBest Paper Digest Alternatives for Medical Literature Summaries (2026)
Explore the best Paper Digest alternatives for medical literature summaries in 2026. Compare Noah AI, Scholarcy, SciSpace, Elicit, and Consensus.
By Linda